Yoshinori Hirashima

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 712 citations · Full text

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma

Natsuko Okita, Ken Kato, Daisuke Takahari et al. · Gastric Cancer · 2011 · 126 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

Junichi Matsubara, Yasuhide Yamada, Yoshinori Hirashima et al. · Clinical Cancer Research · 2008 · 117 citations

Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis

Yoshinori Hirashima, Yasuhide Yamada, Ukihide Tateishi et al. · International Journal of Cancer · 2011 · 66 citations

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Masanori Terashima, Young‐Woo Kim et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 58 citations

Chemotherapy Versus Placebo, Surgical Oncology, Gastrointestinal Oncology +8